Copyright 2016 American Medical Association. All Rights Reserved.
Testing in humans has begun for the Zika Purified Inactivated Virus (ZPIV) vaccine, 1 of 3 candidate vaccine platforms that protected monkeys against the virus in studies conducted earlier this year.
The ZPIV vaccine contains inactivated whole Zika virus particles that cannot cause disease. The intact protein shell of the virus, however, stimulates an immune response against infection. In a study supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), the vaccine induced neutralizing antibodies specific for Zika virus and completely protected rhesus monkeys against virus strains from Brazil and Puerto Rico.
Abbasi J. First Inactivated Zika Vaccine Trial . JAMA. 2016;316(24):2588. doi:10.1001/jama.2016.19328
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: